---
title: "Shandong Weigao Wins CSRC Approval for H Share Full Circulation Plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281428266.md"
description: "Shandong Weigao Group Medical Polymer Co has received approval from the China Securities Regulatory Commission for its H share full circulation plan. This includes converting 48.3 million previously unlisted shares into H shares for trading on the Hong Kong Stock Exchange, enhancing liquidity and broadening its investor base. The approval is valid for 12 months from March 26, 2026. Analysts rate the stock as a Buy with a target price of HK$6.00. The company specializes in medical polymer products and is listed on the Hong Kong Stock Exchange."
datetime: "2026-04-01T17:57:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281428266.md)
  - [en](https://longbridge.com/en/news/281428266.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281428266.md)
---

# Shandong Weigao Wins CSRC Approval for H Share Full Circulation Plan

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) has provided an update.

Shandong Weigao Group Medical Polymer Company Limited has received a filing notice from the China Securities Regulatory Commission approving its plan for H share full circulation. The approval covers the conversion of 48,300,000 previously unlisted shares, representing about 1.06% of its issued share capital, into H shares that will be eligible for listing and trading on the Main Board of the Hong Kong Stock Exchange.

The filing is valid for 12 months from 26 March 2026, during which the company will seek listing and dealing approval from the Hong Kong Stock Exchange for the new H shares. The move is expected to enhance the liquidity of the company’s shares, broaden its investor base, and further integrate its shareholder structure with the international capital market.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.00 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

**More about Shandong Weigao Group Medical Polymer Co**

Shandong Weigao Group Medical Polymer Company Limited is a PRC-incorporated medical device manufacturer focused on medical polymer products and related consumables. The company serves hospital and healthcare markets and is listed in Hong Kong, accessing international capital through its H shares on the Main Board of the Stock Exchange of Hong Kong.

**Average Trading Volume:** 17,919,158

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$16.96B

### Related Stocks

- [01066.HK](https://longbridge.com/en/quote/01066.HK.md)
- [159883.CN](https://longbridge.com/en/quote/159883.CN.md)
- [159898.CN](https://longbridge.com/en/quote/159898.CN.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)

## Related News & Research

- [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md)
- [Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium](https://longbridge.com/en/news/286258287.md)
- [Trump faces record-low approval on inflation as retirees struggle](https://longbridge.com/en/news/286834439.md)
- [Hong Kong’s MPF authority flags fraudulent certificates in early pension payouts](https://longbridge.com/en/news/286657515.md)
- [Shandong Weigao Sets Up Korea-Focused Fund in Connected Deal](https://longbridge.com/en/news/284802061.md)